124 related articles for article (PubMed ID: 38823631)
1. Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma.
Wang J; Xiao P; Li X; Wu W; Shi D; Lin W; Wu Z
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102390. PubMed ID: 38823631
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.
Yang F; Xu GL; Huang JT; Yin Y; Xiang W; Zhong BY; Li WC; Shen J; Zhang S; Yang J; Sun HP; Wang WS; Zhu XL
Front Immunol; 2022; 13():847601. PubMed ID: 35300339
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
6. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
8. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
[TBL] [Abstract][Full Text] [Related]
10. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
11. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.
Gao Y; Lu H; Xiong Z
Front Oncol; 2023; 13():1231359. PubMed ID: 38074659
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
16. Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study.
Guo Y; Wu J; Liang L; Zhu K; Zhou J; Lin L; Chen Y; Cao B; He M; Lian H; Huang W; Cai M
Cancer Imaging; 2023 Sep; 23(1):91. PubMed ID: 37749616
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]